Biomarkers in heart failure: the past, current and future

Michael, Sarhene; Wang, Yili; Wei, Jing; Huang, Yuting; Li, Min; Li, Lan; Acheampong, Enoch; Zhou, Zhengcan; Qin, Xiaoyan; Yunsheng, Xu; Mao, Jingyuan; Gao, Xiumei; Fan, Guanwei

doi:10.1007/s10741-019-09807-z

Cited by 101 publications

(113 citation statements)

References 229 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In these criteria, novel biomarkers need to be able to recognize fundamental causes of heart failure, assess its severity, and foresee the risk of the disease progression. The ACC/AHA guidelines recommended the use of Gal-3 as a biomarker for assessment of myocardial fibrosis in heart failure, however, the ESC has not recommended the clinical use of Gal-3 [101].…”

Section: Established Biomarkers In Heart Diseasementioning

confidence: 99%

Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases

et al. 2020

View full text Add to dashboard Cite

Galectin-3 is a β-galactoside-binding lectin which is important in numerous biological activities in various organs, including cell proliferation, apoptotic regulation, inflammation, fibrosis, and host defense. Galectin-3 is predominantly located in the cytoplasm and expressed on the cell surface, and then often secreted into biological fluids, like serum and urine. It is also released from injured cells and inflammatory cells under various pathological conditions. Many studies have revealed that galectin-3 plays an important role as a diagnostic or prognostic biomarker for certain types of heart disease, kidney disease, viral infection, autoimmune disease, neurodegenerative disorders, and tumor formation. In particular, it has been recognized that galectin-3 is extremely useful for detecting many of these diseases in their early stages. The purpose of this article is to review and summarize the recent literature focusing on the biomarker characteristics and long-term outcome predictions of galectin-3, in not only patients with various types of diseases, but associated animal models.

show abstract

Section: Established Biomarkers In Heart Diseasementioning

confidence: 99%

Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Biomarkers. In the pathogenesis and advancement of different kinds of HF, inflammation is an important factor, and biomarkers of inflammation have now become a significant research area to deal with [122]. e presence of inflammatory cells such as macrophages derived from monocyte and T-lymphocyte at the site of rupture is proceeded by dysfunction of activated endothelial cells which generate adhesion molecules that interact with inflammatory cells [123][124][125].…”

Section: Macrophages and Inflammatorymentioning

confidence: 99%

Macrophage Activities in Myocardial Infarction and Heart Failure

Duncan

Gao

Michael

et al. 2020

Cardiology Research and Practice

Self Cite

View full text Add to dashboard Cite

Heart diseases remain the major cause of death worldwide. Advances in pharmacological and biomedical management have resulted in an increasing proportion of patients surviving acute heart failure (HF). However, many survivors of HF in the early stages end up increasing the disease to chronic HF (CHF). HF is an established frequent complication of myocardial infarction (MI), and numerous influences including persistent myocardial ischemia, shocked myocardium, ventricular remodeling, infarct size, and mechanical impairments, as well as hibernating myocardium trigger the development of left ventricular systolic dysfunction following MI. Macrophage population is active in inflammatory process, yet the clear understanding of the causative roles for these macrophage cells in HF development and progression is actually incomplete. Long ago, it was thought that macrophages are of importance in the heart after MI. Also, though inflammation is as a result of adverse HF in patients, but despite the fact that broad immunosuppression therapeutic target has been used in various clinical trials, no positive results have showed up, but rather, the focus on proinflammatory cytokines has proved more benefits in patients with HF. Therefore, in this review, we discuss the recent findings and new development about macrophage activations in HF, its role in the healthy heart, and some therapeutic targets for myocardial repair. We have a strong believe that there is a need to give maximum attention to cardiac resident macrophages due to the fact that they perform various tasks in wound healing, self-renewal of the heart, and tissue remodeling. Currently, it has been discovered that the study of macrophages goes far beyond its phagocytotic roles. If researchers in future confirm that macrophages play a vital role in the heart, they can be therapeutically targeted for cardiac healing.

show abstract

“…Концентрации циркулирующих маркеров фиброза галектина-3, PICP были выше, а соотношение MMP-9/TIMP-1 уменьшалось у больных СД2 по сравнению с группой конт роля (все р<0,05). Значения PICP были больше у пациентов с СНпФВ по срав нению с пациентами СНсФВ (106,4 (85,4;140,4) нг/мл vs 46,8 (12,6;98,6) нг/мл, соответственно, р=0,043). У больных с СД2 и СН выявлена взаимосвязь между TIMP-1 и конечно-диастолическим объемом ЛЖ (r=-0,68; р=0,042).…”

Section: молекулярный биомаркерный профиль хронической сердечной недоunclassified

“…В последнее десятилетие большое внимание уделяется маркерам миокардиального стресса, таким как N-концевой предшественник мозгового натрийуретического пептида (Nt-proBNP), маркерам воспаления, наиболее доступным и изученным из которых является С-реактивный белок (СРБ), особый интерес вызывают маркеры, ассоциированные с профибротическими процессами: sST2 (стимулирующий фактор роста, экспрессируемый геном 2, растворимая форма, известный также как IL1RL1 и Supression of tumorigenicity 2), галектин-3, С-концевой пропептид проколлагена I типа (PICP), матриксные металлопротеиназы (ММР) и их ингибиторы [6]. Роль каждого из этих биомаркеров достаточно специфична.…”

Section: Molecular Biomarker Profile Of Heart Failure With Mid-range unclassified

“…sST2 -член семейства рецепторов интерлейки на-1, маркер воспаления и миокардиального стресса. Растворимая циркулирующая в кровотоке форма sST2 блокирует кардиопротективный эффект интерлейкина-33, секретируемого в ответ на натяжение миокарда и запускающего каскад реакций, препят ствующих развитию гипертрофии, фиброза и ремоделирования сердца [6,7].…”

Section: Molecular Biomarker Profile Of Heart Failure With Mid-range unclassified

See 1 more Smart Citation

Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes

Лебедев¹,

Лясникова²,

Васильева³

et al. 2020

Russ J Cardiol

View full text Add to dashboard Cite

Aim. To study molecular biomarkers in patients with type 2 diabetes (T2D) in combination with heart failure with preserved (HFpEF) and mid-range ejection fraction (HFmrEF) and compare the data obtained with clinical characteristics of myocardial remodeling.Material and methods. The study included 42 patients with T2D (men — 53%, mean age — 60 years) with clinical manifestations of class II HF: 29 patients with HFpEF (group 1) and 13 patients with HFmrEF (group 2). The control group consisted of 13 healthy people, which were comparable in sex and age and had a normal body mass index (BMI). Patients received stable glucose-lowering and optimal drug therapy for HF for 3 months prior to enrollment in the study. Patients with HFpEF and HFmrEF were comparable in clinical and demographic parameters, had glycated hemoglobin (HbA ) of 8,5% and 8,8%, respectively (p>0,05), increased BMI or grade I-II obesity.We studied following biomarkers: NT-proBNP, highly sensitive C-reactive protein (hsCRP), sST2, galectin-3, procollagen type I C-terminal propeptide (PICP), matrix metalloproteinase 9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1).Results. Volumetric parameters of the left ventricle (LV),LV mass indexed to growth and NT-proBNP were higher in the group of HFpEF patients (p<0,05 for all). The concentrations of galectin-3, PICP were higher, and the MMP-9/TIMP-1 ratio decreased in patients with T2D compared with the control group (p<0,05 for all). PICP values were higher in patients with HFmrEF compared with patients with HFpEF (106,4 (85,4; 140,4) ng/ml vs 46,8 (12,6; 98,6 ng/ml), respectively, p=0,043). In patients with T2D and HF, a relationship was found between TIMP-1 andLV end-diastolic volume (r=-0,68; p=0,042).Conclusion. Patients with HFmrEF and T2D have higherLV volume and mass, higher concentrations of NT-proBNP and PICP in comparison with patients with HFpEF. The direction of MMP-9/TIMP-1 changes may reflect a decrease in antifibrotic processes. Further prospective studies on large samples using a multiple biomarker model are required in T2D and various HF phenotypes.

show abstract

Biomarkers in heart failure: the past, current and future

Cited by 101 publications

References 229 publications

Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases

Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases

Macrophage Activities in Myocardial Infarction and Heart Failure

Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes

Contact Info

Product

Resources

About